Oral vs Injectable Peptides: What Does the Science Say?

The bioavailability problem

Your stomach is designed to destroy peptides. The hydrochloric acid and digestive enzymes (pepsin, trypsin, chymotrypsin) in your gastrointestinal tract exist specifically to break peptide bonds in the proteins you eat, reducing them to individual amino acids for absorption. This is a feature, not a bug. It is how your body digests food.

The consequence for therapeutic peptides is that most of them cannot survive oral administration. This is why insulin, discovered over a century ago, is still delivered by injection. Decades of pharmaceutical research and billions of dollars have gone into developing oral insulin formulations. The challenge is that daunting.

Bioavailability is the percentage of a substance that reaches systemic circulation in its active form after administration. For most injectable peptides, bioavailability by subcutaneous injection is high, typically 70 to 100 percent, because the peptide bypasses the digestive tract entirely and enters the bloodstream through surrounding capillaries. For oral peptides, bioavailability is usually in the single digits or zero.

BPC-157 is a genuine exception

BPC-157 is derived from a protein that evolved to function in human gastric juice. Its amino acid sequence gives it unusual stability in the exact acidic, enzyme-rich environment that destroys other peptides. This is not marketing language. It is a biochemical property that has been confirmed in stability studies showing BPC-157 remains intact in gastric fluid (Jozwiak et al., Pharmaceuticals, 2025, PMC11859134).

This acid stability is what makes oral dosing a legitimate topic for BPC-157 specifically. In animal studies, oral BPC-157 has demonstrated clear effects on gastrointestinal tissues, including healing gastric ulcers, intestinal lesions, and inflammatory bowel models. The peptide contacts the gut lining directly, so local effects in the GI tract do not require systemic absorption.

The honest gap: no published study has measured the oral bioavailability of BPC-157, meaning how much actually reaches the bloodstream after oral dosing, in any species. The percentage figures sometimes quoted online (ranging from 5 percent to 20 percent) are estimates, not measured values. For GI-related effects, oral delivery has a clear rationale because the peptide acts locally. For a distant target like a knee or shoulder, the case for oral dosing is significantly weaker because systemic delivery remains unquantified.

Why TB-500 requires injection

TB-500 does not share BPC-157's acid stability. As a fragment of thymosin beta-4, it has no evolutionary relationship to the digestive tract and no special resistance to digestive enzymes. Oral TB-500 would be broken down into inactive fragments before reaching the bloodstream.

This is why TB-500 is administered by subcutaneous injection in both research and clinical contexts. The injection route preserves the peptide's structure and delivers it directly into systemic circulation, where it can exert its effects on cell migration and inflammation throughout the body (Thymosin Beta-4 Scoping Review, Applied Sciences, 2026).

GHK-Cu and delivery challenges

GHK-Cu presents its own delivery considerations. As a topical, it has demonstrated clinical effects in skincare studies but has limited skin penetration on its own, which is why commercial formulations use specialized delivery vehicles like liposomes or carrier molecules. Orally, it would face the same digestive degradation as most peptides. Injectable formulations bypass both barriers but raise the question of how long the tripeptide persists at effective concentrations given its rapid clearance from plasma.

Subcutaneous vs intramuscular vs intravenous

For injectable peptides, the route of injection also matters. Subcutaneous injection (under the skin) is the most common method for recovery peptides. It provides slower, more sustained absorption than intramuscular injection, and is simpler for self-administration. Intramuscular injection delivers the peptide deeper and may provide slightly faster absorption for some compounds. Intravenous administration, used in the BPC-157 safety pilot by Lee and Burgess (2025), provides immediate systemic delivery but requires medical supervision and showed that BPC-157 clears to baseline within 24 hours.

The appropriate route depends on the peptide, the target tissue, and the clinical context. This is a decision for a qualified prescriber, not a personal experiment.

The bottom line on delivery routes

For gut-related effects, oral BPC-157 has a logical biological basis supported by animal data. For musculoskeletal or systemic recovery goals, injection is the route that preserves peptide integrity and the route used in nearly all relevant research. No oral formulation of any recovery peptide has demonstrated systemic therapeutic effects in published human studies. And no delivery route for these peptides is FDA-approved, so any use is a clinical decision made with a licensed provider using product from a legitimate source.